SCYX (scynexis.com) Net earnings per share (EPS TTM)

scynexis.com (SCYX) - corporate logo

Competition risks and cheap generics are constraining revenue, yet the transition to a royalty-based licensing model has minimized costs. The change in the rolling annual EPS demonstrates actual plan execution, and -1.19 becomes the new value for this metric. The resilience of pharmacy channels and control over raw material supply chains allow SCYNEXIS, Inc. (SCYX) to maintain high production margins for antifungal agents.

SCYX (Scynexis) Net earnings per one share for the last twelve months history from 07/04/2022 to 11/10/2026

SCYNEXIS Inc (SCYX) - metric breakdowns and financial figures

- current quotes and average value forecast:
Price Chart Scynexis|SCYX - Broker Consensus Forecast
- business market valuation indicators:
Market Capitalization SCYNEXIS, Inc.|SCYX - Full Business Value
- business book valuation details:
Book Value per Share SCYNEXIS|SCYX - Total Stockholders' Equity|Market Capitalization to Book Value Ratio scynexis.com|SCYX - Cumulative Company Assets
- debt and solvency information:
Total Debt to Equity Ratio SCYNEXIS, Inc.|SCYX - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Scynexis|SCYX - Company Total Debt Obligations|Debt to Book Capitalization Ratio SCYNEXIS, Inc.|SCYX - Long-Term Debt|Company Short-Term Debt SCYNEXIS|Quick Liquidity scynexis.com
- net income and valuation multiples indicators:
SCYX - Net Financial Result|Expected Profit SCYNEXIS, Inc.|SCYX - Business Payback Period|Forward P/E Multiple Scynexis|SCYX - Price/Earnings to Growth Multiple|Enterprise Value to EBITDA Ratio SCYNEXIS, Inc.|SCYX - Profit before interest, taxes and amortization|Earnings per share for the last twelve months SCYNEXIS|SCYX - Earnings per share for the last 12 months|Quarterly EPS earnings growth scynexis.com|SCYX - Earnings per share growth rate in current year|Expected earnings per share growth for next year SCYNEXIS, Inc.
Fundamental company analysis:SCYX - scynexis.com
Flagship merchandise of SCYNEXIS Inc

Professional capital evaluates the profile of SCYNEXIS, Inc. (SCYX) through the dynamics of real income generation. The fundamental TTM net income per share metric aggregates earnings over the last four quarters, distributing them across the total volume of issuance. Analyzing this curve allows for the rapid identification of declining profitability. For this developer of innovative antifungal agents, such a metric reflects the efficiency of drug commercialization within the hospital and pharmacy segments. Steady growth of this indicator confirms the investment reliability of the asset.

Main competitors

SMMT - Earnings per share for the last twelve months|MRNA (modernatx.com) - Earnings per share for the last 12 months|PCVX: Net earnings per share (EPS TTM)|Earnings per one share for the last 12 months TARS (Tarsus Pharmaceuticals Inc)|CRMD (CorMedix Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Seres Therapeutics, Inc MCRB|Net earnings per share (EPS TTM) SPRO|Net earnings per share for the last 12 months an2therapeutics.com ANTX|PolyPid - Net earnings per share for the last 12 months|Earnings per share for the last four quarters LSB (LakeShore Biopharma Co., Ltd.)|Iterum Therapeutics, plc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters BiomX Inc. PHGE|soligenix.com (SNGX) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months 60 Degrees Pharmaceuticals, Inc. (SXTP)|Earnings per share for the last twelve months Oragenics|Earnings per share for the last 12 months OPGN (OpGen Inc)